Edition:
United States

Puma Biotechnology Inc (PBYI.OQ)

PBYI.OQ on NASDAQ Stock Exchange Global Select Market

99.60USD
12 Dec 2017
Change (% chg)

$-1.55 (-1.53%)
Prev Close
$101.15
Open
$101.75
Day's High
$102.05
Day's Low
$98.60
Volume
147,974
Avg. Vol
237,114
52-wk High
$136.90
52-wk Low
$28.35

Select another date:

BRIEF-Daiichi Sankyo And Puma Biotechnology To Collaborate With Major Cancer Center In HER2-Mutated Cancer

* DAIICHI SANKYO AND PUMA BIOTECHNOLOGY ANNOUNCE RESEARCH COLLABORATION WITH MAJOR CANCER CENTER IN HER2-MUTATED CANCER Source text for Eikon: Further company coverage:

BRIEF-Puma Biotechnology Announces Positive Outcome Of European Opposition Proceedings

* PUMA BIOTECHNOLOGY ANNOUNCES POSITIVE OUTCOME OF EUROPEAN OPPOSITION PROCEEDINGS

BRIEF-PUMA BIOTECHNOLOGY, SPECIALISED THERAPEUTICS ASIA AGREE TO COMMERCIALIZE NERLYNX IN SOUTH EAST ASIA

* PUMA BIOTECHNOLOGY AND SPECIALISED THERAPEUTICS ASIA ENTER INTO EXCLUSIVE LICENSING AGREEMENT TO COMMERCIALIZE NERLYNX® (NERATINIB) IN AUSTRALIA, NEW ZEALAND AND SOUTH EAST ASIA

BRIEF-Puma Biotechnology reports Q3 adj. loss per share $1.36

* Puma Biotechnology reports third quarter 2017 financial results

BRIEF-Puma Biotechnology secures $100 mln term loan from Silicon Valley Bank and Oxford Finance

* Puma Biotechnology secures $100 million term loan from Silicon Valley Bank and Oxford Finance

Former Puma Biotech executive pleads guilty to insider trading

BOSTON, Nov 2 A former Puma Biotechnology Inc executive pleaded guilty on Thursday to U.S. charges that he traded on inside information ahead of announcements by the biopharmaceutical company about a drug it was developing to treat breast cancer.

BRIEF-Puma Biotechnology reports Q2 loss per share $2.10

* Puma Biotechnology reports second quarter 2017 financial results

U.S. FDA approves Puma Biotech's breast cancer treatment

The U.S. Food and Drug Administration (FDA) on Monday approved Puma Biotechnology Inc's experimental breast cancer drug that lowers the risk of the disease returning after initial treatment.

UPDATE 2-U.S. FDA approves Puma Biotech's breast cancer treatment

July 17 The U.S. Food and Drug Administration (FDA) on Monday approved Puma Biotechnology Inc's experimental breast cancer drug that lowers the risk of the disease returning after initial treatment.

BRIEF-U.S. FDA approves Puma's Nerlynx for extended adjuvant treatment of HER2-positive early stage breast cancer

* U.S. Food and Drug Administration approves Puma's Nerlynx (neratinib) for extended adjuvant treatment of HER2-positive early stage breast cancer

Select another date: